TimesSquare Capital Management LLC Has $15.70 Million Stock Holdings in Krystal Biotech, Inc. $KRYS

TimesSquare Capital Management LLC trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 19.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 114,204 shares of the company’s stock after selling 27,979 shares during the period. TimesSquare Capital Management LLC owned about 0.39% of Krystal Biotech worth $15,698,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in KRYS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after purchasing an additional 365,304 shares during the last quarter. Nuveen LLC bought a new position in Krystal Biotech during the 1st quarter valued at about $42,223,000. Braidwell LP increased its position in shares of Krystal Biotech by 99.9% during the 1st quarter. Braidwell LP now owns 400,744 shares of the company’s stock valued at $72,254,000 after purchasing an additional 200,244 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in Krystal Biotech in the 1st quarter worth approximately $33,455,000. Finally, 1832 Asset Management L.P. purchased a new position in shares of Krystal Biotech during the first quarter valued at about $24,521,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $203.03 on Thursday. The firm has a market cap of $5.89 billion, a PE ratio of 30.44 and a beta of 0.65. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $212.98. The firm’s 50 day moving average price is $177.73 and its two-hundred day moving average price is $154.67.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. The company had revenue of $97.80 million during the quarter, compared to analysts’ expectations of $93.72 million. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. Equities analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on KRYS shares. Guggenheim set a $224.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. HC Wainwright restated a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Monday, September 15th. Bank of America lifted their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Finally, Chardan Capital increased their price target on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Krystal Biotech currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.14.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).